Citations

Clear

9383 citation(s) found for "Thomas, PS".

Core outcomes in nerve surgery: development of a core outcome set for ulnar neuropathy at the elbow
Wilson, Thomas J. , Davis, Gavin A , Guedes, Fernando , Hébert‐Blouin, Marie‐Noëlle, Jack, Megan M. , Jacques, Line , Kretschmer, Thomas , Midha, Rajiv, Puffer, Ross C. , Rasulić, Lukas , Ray, Wilson Z. , Rizk, Elias , Rodríguez-Aceves, Carlos Alberto , Shapira, Yuval, Spinner, Robert J. , Zager, Eric L. , Davis, Gavin A. , Dengler, Nora F. , Mahan, Mark A , Pondaag, Willem , Smith, Brandon W. , Socolovsky, Mariano

Mayo Clinic

Journal of Neurosurgery | August 12, 2023 | Volume: 140 | Issue: 2 | Pages: 489-497

10.3171/2023.6.jns23702 | PMID 37877978 Get It

OBJECTIVE Ulnar neuropathy at the elbow (UNE) is common, affecting 1%–6% of the population. Despite this, there remains a lack of consensus regarding optimal treatment. This is primarily due to the difficulty one encounters when trying to assess the literature. Outcomes are inconsistently reported, which makes comparing studies or developing meta-analyses difficult or even impossible. Thus, there is a need for a core outcome set (COS) for UNE (COS-UNE) to help address this problem. The objective of this study was to utilize a modified Delphi method to develop COS-UNE. METHODS A 5-stage approach was utilized to develop COS-UNE: stage 1, consortium development; 2, literature review to identify potential outcome measures; 3, Delphi survey to develop consensus on outcomes for inclusion; 4, Delphi survey to develop definitions; and 5, consensus meeting to finalize the COS and definitions. The study followed the Core Outcome Set-STAndards for Development (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 21 participants, all neurological surgeons representing 11 countries. The final COS-UNE consisted of 22 data points/outcomes covering the domains of demographic characteristics, diagnostics, patient-reported outcomes, motor/sensory outcomes, and complications. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 6 months, with the consensus optimal timepoints for assessment identified as preoperatively and 3, 6, and 12 months postoperatively. CONCLUSIONS The authors identified consensus data points/outcomes and also provided definitions and specific scales to be utilized to help ensure that clinicians are consistent in their reporting across studies on UNE. This COS should serve as a minimum set of data to be collected in all future neurosurgical studies on UNE. The authors hope that clinicians evaluating ulnar neuropathy will incorporate this COS into routine practice and that future studies will consider this COS in the design phase.
Accuracy of the Early Diagnosis of Parkinson's Disease
Beach, Thomas G. , Adler, Charles H. , Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Adler, C H , Zhang, Nan , Serrano, Geidy E.

Mayo Clinic

Movement Disorders | August 11, 2023 | Volume: 38 | Issue: 8 | Pages: 1573-1574

10.1002/mds.29556 | PMID 37565398 Get It

The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma
Pappas, Leontios , Baiev, Islam , Reyes, Stephanie , Bocobo, Andrea Grace, Jain, Apurva , Spencer, Kristen , Rahma, Osama E. , Maurer, Jordan R., Stanton, Jen, DeLeon, Thomas, Roth, Marc, Zhu, Andrew X. , Boyhen, Kylie, VanCott, Christine, Roberts, Lewis R. , Lindsey, Stacie , Lennerz, Jochen K. , Iafrate, A. John , Goff, Laura W. , Mody, Kabir , Shroff, Rachna T. , Javle, Milind , Kelley, Robin Katie, Rahma, Osama E , Zhang, Karen , De Armas, Anaemy Danner , DeLeon, Thomas T, Roth, Marc , Peters, Mary Linton B , Zhu, Andrew X , Roberts, Lewis R , Lindsey, Stacie , Lennerz, Jochen , Goff, Laura Williams , Mody, Kabir , Borad, Mitesh J , Javle, Milind M , Kelley, R Katie , Goyal, Lipika , Spencer, Kristen , Pappas, Leontios , Le, Tri Minh , Stanton, Jennifer R., Patel, Tushar , Horick, Nora , Borad, Mitesh J. , Kelley, Robin Kate , Goyal, Lipika

Mayo Clinic

JCO Precision Oncology | August 10, 2023 | Volume: No volume available | Issue: 7 | Pages: No page available

10.1200/po.22.00594 | PMID 37561981 Get It

PURPOSE Increased awareness of the distinct tumor biology for adolescents and young adults (AYAs) with cancer has led to improvement in outcomes for this population. However, in cholangiocarcinoma (CCA), a paucity of data exist on the AYA population. To our knowledge, we present the largest study to date on AYA disease biology, treatment patterns, and survival outcomes in CCA. METHODS A multi-institutional cohort of patients with CCA diagnosed with intrahepatic cholangiocarcinoma (ICC) or extrahepatic cholangiocarcinoma (ECC) was used for analysis. Retrospective chart review was conducted on patients who were 50 years old and younger (young; n = 124) and older than 50 years (older; n = 723). RESULTS Among 1,039 patients screened, 847 patients met eligibility (72% ICC, 28% ECC). Young patients had a larger median tumor size at resection compared with older patients (4.2 v 3.6 cm; P = .048), more commonly had N1 disease (65% v 43%; P = .040), and were more likely to receive adjuvant therapy (odds ratio, 4.0; 95% CI, 1.64 to 9.74). Tumors of young patients were more likely to harbor an FGFR2 fusion, BRAF mutation, or ATM mutation ( P < .05 for each). Young patients were more likely to receive palliative systemic therapy (96% v 69%; P < .001), targeted therapy (23% v 8%; P < .001), and treatment on a clinical trial (31% v 19%; P = .004). Among patients who presented with advanced disease, young patients had a higher median overall survival compared with their older counterparts (17.7 v 13.5 months; 95% CI, 12.6 to 22.6 v 11.4 to 14.8; P = .049). CONCLUSION Young patients with CCA had more advanced disease at resection, more commonly received both adjuvant and palliative therapies, and demonstrated improved survival compared with older patients. Given the low clinical trial enrollment and poor outcomes among some AYA cancer populations, data to the contrary in CCA are highly encouraging.
Novel NFkB Variant V213E: Phenotypic Description & Molecular Modeling
Chaudhri, Eman N. , Weber, Caleb A., Savytskyi, Oleksandr V. , Squire, Jacqueline D. , Wierenga, Klaas J. , Coban, Matt , Squire, Jacqueline , Caulfield, Thomas R.

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 167.05-167.05

10.4049/jimmunol.210.supp.167.05 Get It

Abstract BACKGROUND Mutations of NFkB1 are a known cause of inborn errors of immunity resulting in immunodeficiency due to the role of NFkB1 as a transcriptional regulator of immunomodulating proteins. We present a patient with a diagnosis of common variable immunodeficiency (CVID), cytopenias with massive splenomegaly, and nodular regenerative hyperplasia of the liver. Our proband, a 22-year-old male, presents with a clinical picture of immunodeficiency, and has a maternal cousin with a similar gene mutation but differing phenotype. Next generation panel sequencing (NGPS) was utilized to discover a novel, single point mutation variant in NFkB1, V213E, that is present in our proband. METHODS The novel single-point mutation V213E in the NFkB gene was modeled in-silico using the I-TASSER homology modeling software. Molecular dynamics simulations of both the wild type and variant mutant form fitted to accommodate the novel mutation were conducted and analyzed to assess for possible pathogenicity of the novel mutation. RESULTS This variant replaces Valine with Glutamic Acid at position 213 in the transcription regulator’s sequence. We perform molecular modeling to analyze the proteomic impact and difference in molecular dynamics (MDS) which depicted suppressed dynamics in the ankyrin region and death domain of the protein complex. Analysis of the proband’s family showed no significant family history except for the maternal cousin with a mutation in NFkB1. CONCLUSION This case both highlights the heterogeneity in phenotype of NFkB1 pathogenic variants as shown in this patient, full penetrance of the variant mutation, and suggests the pathogenicity of a new variant through protein modeling techniques and molecular dynamic simulations.
Multiparameter cellular and humoral immunoprofiling to differentiate progressive from nonprogressive non-tuberculous mycobacterial lung disease (NTM-LD)
Pathakumari, Balaji , Marty, Paige K. , Vadiyala, Mounika Reddy , Cox, Thomas C., Keulen, Virginia Van, Shah, Maleeha, Peikert, Tobias, Patricio, escalante, Cox, Thomas, Keulen, Virginia P. Van , Shah, Maleeha

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 81.22-81.22

10.4049/jimmunol.210.supp.81.22 Get It

Abstract Background Biomarkers that predict the patients most likely to develop progressive NTM-LD are urgently needed. We hypothesize flow cytometric (FC) detection of T cell markers after ex vivo antigen challenge in PBMC can differentiate patients with progressive vs. nonprogressive NTM-LD. We also measured the serum anti-glycopeptidolipid core IgA antibody by commercial ELISA kit and compared with FC immunoprofiling results. Methods PBMCs were isolated from patients with NTM-LD and stimulated with purified protein derivative (PPD), mycobacteria-specific peptide pools (MTB300, RD1-peptides). We have performed ELISA and FC T-cell phenotypic assays to measure diagnostic accuracy of these assays by ROC and non-parametric statistics analysis. Results A total of 29 NTM-LD patients were studied and classified into 15 non-progressive and 14 progressive NTM-LD based on radiological and clinical evaluation. Patients with progressive NTM-LD showed a statistically significantly higher frequency of PPD-specific CD3+/CD8+ IFN-γ+HLA-DR+ subsets and high diagnostic accuracy compared with non-progressors: Sensitivity = 80% specificity = 71.4% with the ROC of 0.72. There were no other statistically significant differences in other antigen-stimulated T-cell subsets but a trend was observed with HLA-DR+TNF-α+, CD25+CD134+ and CD25+PDL1+ T-cell subsets in progressors. The anti-GPL IgA levels did not show a significant difference and might not be useful in distinguishing progressive from non-progressive NTM-LD. Conclusion Our study findings suggest that PPD-specific CD8+ IFN-γ+HLA-DR+ can distinguish progressive and nonprogressive NTM-LD patients, which can identify those patients at risk of disease progression.
P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA-3 SUBGROUP ANALYSIS BY PRIOR LINES OF THERAPY
Manier, Salomon , Mateos, María‐Victoria , Munshi, Nikhil C. , Arnulf, Bertrand , Vij, Ravi , Broijl, Annemiek , Sborov, Douglas W. , Iida, Shinsuke , Truppel-Hartmann, Anna, Yang, Zhihong, Piasecki, Julia , Felten, Jasper, Caia, Andrea, Rodríguez‐Otero, Paula , Einsele, Hermann , Bahlis, Nizar Jacques , Ailawadhi, Sikander , Nooka, Ajay K. , Abrahamsen, Ingerid Weum , Jagannath, Sundar , Benjamin, Reuben , Gergis, Usama , Cook, Mark , Baz, Rachid

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e3385948

10.1097/01.hs9.0000970368.33859.48 Get It

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY
Abonour, Rafat , Rifkin, Robert M. , Gasparetto, Christina, Durie, Brian G.M. , Terebelo, Howard R. , Narang, Mohit , Toomey, Kathleen, Tang, Yuexin , Dhanasiri, Sujith, Anand, Jasmeet, Yu, Edward, Marshall, Thomas, Liu, Liang , Ailawadhi, Sikander , Lee, Hans C. , Wagner, Lynne I. , Hardin, James W. , Jagannath, Sundar

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e52503e2

10.1097/01.hs9.0000970564.52503.e2 Get It

P1152: DEPTH OF METABOLIC RESPONSE AT INTERIM PET AND SURVIVAL OUTCOMES AMONG PATIENTS WITH PRIMARY REFRACTORY OR EARLY RELAPSING DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Bock, Allison M. , Mwangi, Raphael , Ataei, Fatemeh , Pritchett, Josh, Shreve, Jacob , Khurana, Arushi , Nowakowski, Grzegorz S. , Thorpe, Matthew , Maurer, Matthew J. , Paludo, Jonas , Cerhan, James R. , Witzig, Thomas E. , Habermann, Thomas M. , Wang, Yucai , Young, Jason R.

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e6583552

10.1097/01.hs9.0000971504.65835.52 Get It

P936: EXPLORING HETEROGENEITY IN TREATMENT PREFERENCES OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN THE UNITED STATES, UNITED KINGDOM, FRANCE, SPAIN, ITALY AND GERMANY
Popat, Rakesh , Kleinman, David , Perera, Sue, Gorsh, Boris , Mulnick, Sarah, Alicia, Oneill, Hanna, Maya, Molinari, Alexa , Gelhorn, Heather L. , Popat, Rakesh , Ailawadhi, Sikander , Thomas, Caitlin , Ross, Melissa

Mayo Clinic

HemaSphere | August 9, 2023 | Volume: 7 | Issue: S3 | Pages: e989881c

10.1097/01.hs9.0000970648.98988.1c Get It

Medically ready for discharge: A multisite “point‐in‐time” assessment of hospitalized patients
Bann, Maralyssa , Meo, Nicholas , Ou, Amy , Rosenthal, M , Khawaja, Hussain , Goodman, Leigh Anne , Barone, Melanie, Coleman, Bernice , High, Heidi , Overbeek, Lori, Shelbourn, Pam, VerMaas, Lisa, Baughman, Amy W. , Sekaran, Adith, Cyrus, Rachel , O'Dorisio, Nathan, Beatty, Lane, Loica‐Mersa, Silvia , Kubey, Alan , Jaffe, Rebecca, Vokoun, Chad, Koom‐Dadzie, Kwame , Graves, Kencee , Helgerson, Paul , Ou, Amy , Rosenthal, Molly , Khawaja, Hussain , Goodman, Leigh A , Baughman, Amy , Loica-Mersa, Silvia , Kubey, Alan A , Koom-Dadzie, Kwame , Graves, Kencee , Tuck, Matthew , Helgerson, Paul , Lopez, J. P.

Mayo Clinic

Journal of Hospital Medicine | August 9, 2023 | Volume: 18 | Issue: 9 | Pages: 795-802

10.1002/jhm.13184 | PMID 37553979 Get It

Abstract Background Time spent awaiting discharge after the acute need for hospitalization has resolved is an important potential contributor to hospital length of stay (LOS). Objective To measure the prevalence, impact, and context of patients who remain hospitalized for prolonged periods after completion of acute care needs. Design, Setting, and Participants We conducted a cross‐sectional “point‐in‐time” survey at each of 15 academic US hospitals using a structured data collection tool with on‐service acute care medicine attending physicians in fall 2022. Main Outcomes and Measures Primary outcomes were number and percentage of patients considered “medically ready for discharge” with emphasis on those who had experienced a “major barrier to discharge” (medically ready for discharge for ≥1 week). Estimated LOS attributable to major discharge barriers, contributory discharge needs, and associated hospital characteristics were measured. Results Of 1928 patients sampled, 35.0% ( n = 674) were medically ready for discharge including 9.8% ( n = 189) with major discharge barriers. Many patients with major discharge barriers (44.4%; 84/189) had spent a month or longer medically ready for discharge and commonly (84.1%; 159/189) required some form of skilled therapy or daily living support services for discharge. Higher proportions of patients experiencing major discharge barriers were found in public versus private, nonprofit hospitals (12.0% vs. 7.2%; p = .001) and county versus noncounty hospitals (14.5% vs. 8.8%; p = .002). Conclusions Patients experience major discharge barriers in many US hospitals and spend prolonged time awaiting discharge, often for support needs that may be outside of clinician control.